Top

Published in:

01-04-2009 | Original Article

Prognostic value of myocardial perfusion-gated SPECT in patients with ischemic cardiomyopathy

Authors: Jaume Candell-Riera, MD, PhD, FESC, Guillermo Romero-Farina, MD, PhD, FESC, Santiago Aguadé-Bruix, MD, Joan Castell-Conesa, MD, PhD, Gustavo de León, MD, David García-Dorado, MD, PhD, FESC

Published in: Journal of Nuclear Cardiology | Issue 2/2009

Abstract

Background

There are no extensive series in which risk stratification of patients with ischemic cardiomyopathy (IC) is based on their rest and exercise and scintigraphic characteristics. The purpose of our study was to analyze rest and exercise myocardial perfusion-gated SPECT variables for prognosis in patients with ischemic IC.

Methods and Results

Prospective cohort study. A study was performed in 167 patients with IC who consecutively underwent rest myocardial perfusion-gated SPECT. In addition, stress SPECT was performed on 137 of these patients. During an average follow-up of 2.3 ± 1.2 years, cardiac mortality (CM) was 17.4%. Independent predictors of CM in rest-gated SPECT were the positive criteria for myocardial viability (P = 0.027; Hazard risk, HR: 5.1; 95% CI: 1.2-21.4). In the 137 patients who underwent stress-gated SPECT, predictors were scintigraphic criteria for viability plus ischemia (P = 0.026; HR: 3.6; 95% CI: 1.16-11.2) and exercise duration ≤5 minutes (P = 0.04; HR: 2.7; 95% CI: 1.01-7.36). Coronary angiography variables, performed in 111 patients, did not significantly modify the prognostic value of non-invasive testing.

Conclusion

Myocardial perfusion-gated SPECT improves prognostic stratification of patients with IC.

Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003;42:736-42.CrossRefPubMed

Gheorghiade M, Cody RJ, Francis CS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Am Heart J 1998;135:S231-48.CrossRefPubMed

Moster A, Hoes AW, Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J 1999;20:447-55.CrossRef

Sharir T, Germano G, Kang X, Lewin HC, Miranda R, Cohen I, et al. Prediction of myocardial infarction versus cardiac death by gated myocardial perfusion SPECT: Risk stratification by the amount of stress-induced ischemia and the poststress ejection fraction. J Nucl Med 2001;42:831-7.PubMed

Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.CrossRefPubMed

González JM, Castell-Conesa J, Candell-Riera J, Rossello-Urgell J, Spanish Working Group of Nuclear Cardiology. Relevance of ^99mTc-MIBI rest uptake, ejection fraction and contractile abnormality location in predicting myocardial recovery after revascularization. Nucl Med Commun 2001;22:795-805.CrossRefPubMed

Romero-Farina G, Candell-Riera J, Aguadé-Bruix S, Castell-Conesa J, de León G. Analysis of apical remodeling in gated myocardial perfusion SPECT imaging in ischemic cardiomyopathy. J Nucl Cardiol 2008;15:225-31.CrossRefPubMed

Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995;36:2138-47.PubMed

Candell-Riera J, Santana-Boado C, Bermejo B, Aguade-Bruix S, Bermejo-Fraile B, Soler-Soler J. Dipyridamole administration at the end of an insufficient exercise ^99mTc-MIBI SPECT improves detection of multivessel coronary artery disease in patients with previous myocardial infarction. Am J Cardiol 2000;85:532-5.CrossRefPubMed

10.

Gibbons RJ, Miller TD. Tc-99m sestamibi infarct size as a surrogate endpoint. J Nucl Cardiol 2005;12:12-9.CrossRefPubMed

11.

Ridker PM, Cook N. Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program. Circulation 2005;111:657-8.CrossRefPubMed

12.

Vasan RS, D′Agostino RB. Age and time need not and should not be eliminated from the coronary risk prediction models. Circulation 2005;111:542-5.CrossRefPubMed

13.

Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.PubMed

14.

Bittner V. Exercise testing in heart failure. Maximal, submaximal, or both? J Am Coll Cardiol 2003;42:123-5.CrossRefPubMed

15.

Myers J, Gullestad L. The role of exercise testing and gas-exchange measurement in the prognosis assessment of patients with heart failure. Curr Opin Cardiol 1998;13:145-55.PubMed

16.

Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.PubMed

17.

Cohen-Solal A, Barnier P, Pessione F, Seknadji P, Logeart D, Laperche T, et al. Comparison of the long-term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure. Heart 1997;78:572-6.PubMed

18.

Opasich C, Pinna GD, Bobbio M, Sisti M, Demichelis B, Febo O, et al. Peak exercise oxygen consumption in chronic heart failure: Toward efficient use in the individual patient. J Am Coll Cardiol 1998;31:766-75.CrossRefPubMed

19.

Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, et al. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. Am Heart J 2000;139:78-84.CrossRefPubMed

20.

Bruner-La Roca HP, Weilenmann D, Follath F. Oxygen uptake kinetics during level exercise in patients with heart failure: Relation to neurohormones, peak oxygen consumption and clinical findings. Heart 1999;81:121-7.

21.

Lauer MS, Snader CE. Using exercise testing to prognosticate patients with heart failure. Which parameter should we measure? Clin Cardiol 2001;19:573-81.CrossRef

22.

Sharir T. Role of regional myocardial dysfunction by gated myocardial perfusion SPECT in the prognostic evaluation of patients with coronary artery disease. J Nucl Cardiol 2005;12:5-7.CrossRefPubMed

23.

Kitsiou AN, Srinivasan G, Quyyumi AA, Summers RM, Bacharach SL, Dilsizian V. Stress-induced reversible and mild-to-moderate irreversible thallium defects. Are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation 1998;98:501-8.PubMed

24.

Meluzín J, Cerney J, Frélich M, Stetka F, Spinarova L, Popelova , et al. Prognosis value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 1998;32:912-20.CrossRefPubMed

25.

Bourque J, Hasselblad V, Velazquez EJ, Borges-Neto S, O’Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: A meta-analysis. Am Heart J 2003;146:621-7.CrossRefPubMed

26.

Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002;39:1151-8.CrossRefPubMed

27.

Senior R, Lahiri A, Kaul S. Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. Am J Cardiol 2001;88:624-9.CrossRefPubMed

28.

Senior R, Kaul S, Raval U, Lahiri A. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 2002;9:454-62.CrossRefPubMed

29.

Cleland JGF, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial. Lancet 2003;362:14-21.CrossRefPubMed

Title: Prognostic value of myocardial perfusion-gated SPECT in patients with ischemic cardiomyopathy
Authors: Jaume Candell-Riera, MD, PhD, FESC
Guillermo Romero-Farina, MD, PhD, FESC
Santiago Aguadé-Bruix, MD
Joan Castell-Conesa, MD, PhD
Gustavo de León, MD
David García-Dorado, MD, PhD, FESC
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Journal of Nuclear Cardiology / Issue 2/2009
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-008-9042-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic value of myocardial perfusion-gated SPECT in patients with ischemic cardiomyopathy

Abstract

Background

Methods and Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2009

ASNC Announcement

Of fight and flight

ASNC Announcement

Molecular imaging of platelet activation in thrombus

Applications of optical coherence tomography in cardiovascular medicine, part 1

Validation of attenuation correction using transmission truncation compensation with a small field of view dedicated cardiac SPECT camera system